Longeveron Publishes Results Of Phase 2a Clinical Trial Evaluating Laromestrocel In Alzheimer's Disease In Nature Medicine

Benzinga · 03/11 12:31
  • Phase 2a results demonstrated laromestrocel (Lomecel-B™) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's disease
  • This encouraging clinical trial data adds to the body of evidence supporting the safety of single and multiple doses of laromestrocel (Lomecel-B™) treatment for mild Alzheimer's disease and provides indications of efficacy in combating decline of brain volume and potentially cognitive function
  • Laromestrocel (Lomecel-B™) is, to Company's knowledge, the first cellular therapeutic candidate to receive U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer's disease